Peptides for Cancer Treatment
Overview
7 research peptides are currently studied for cancer treatment. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Leuprolide — Approved Medication with Strong Human Data
Evidence Rating: A Category: Reproductive / Hormonal
Leuprolide (leuprorelin) is a synthetic GnRH (gonadotropin-releasing hormone) agonist nonapeptide (MW ~1209.4 g/mol) that is one of the most widely prescribed hormonal therapies in oncology and reproductive medicine. It is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, c...
Key claims: Effective androgen deprivation therapy for prostate cancer; Treats endometriosis-associated pain.
Goserelin — Approved Medication with Strong Human Data
Evidence Rating: A Category: Reproductive / Hormonal
Goserelin is a synthetic GnRH agonist decapeptide analog (MW ~1269.4 g/mol) delivered as a biodegradable PLGA implant (Zoladex) injected subcutaneously in the anterior abdominal wall. It is FDA-approved for advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before ablat...
Key claims: Effective androgen deprivation in prostate cancer; Adjuvant treatment for premenopausal breast cancer.
Triptorelin — Approved Medication with Strong Human Data
Evidence Rating: A Category: Reproductive / Hormonal
Triptorelin is a synthetic GnRH agonist decapeptide analog (MW ~1311.4 g/mol) with a D-Trp substitution at position 6 of native GnRH. It is FDA-approved for the palliative treatment of advanced prostate cancer (Trelstar) and for central precocious puberty (Triptodur). Available as intramuscular depo...
Key claims: Achieves effective castration in prostate cancer; Effectively suppresses puberty in central precocious puberty.
Histrelin — Approved Medication with Strong Human Data
Evidence Rating: A Category: Reproductive / Hormonal
Histrelin is a synthetic GnRH agonist nonapeptide analog (MW ~1323.5 g/mol) with a D-His(benzyl) substitution at position 6. It is FDA-approved as a subdermal implant for advanced prostate cancer (Vantas, 50 mg implant releasing ~50 mcg/day for 12 months) and central precocious puberty (Supprelin LA...
Key claims: Provides 12 months of continuous testosterone suppression; Effective long-term treatment for central precocious puberty.
Degarelix — Approved Medication with Strong Human Data
Evidence Rating: A Category: Reproductive / Hormonal
Degarelix is a synthetic GnRH antagonist (MW ~1632.3 g/mol) and the first injectable GnRH receptor blocker approved for advanced prostate cancer. FDA-approved in 2008 (Firmagon), it produces immediate suppression of LH, FSH, and testosterone without the initial hormonal flare seen with GnRH agonists...
Key claims: Achieves rapid testosterone suppression without flare; Non-inferior to leuprolide for testosterone suppression.
Buserelin — Approved Medication with Strong Human Data
Evidence Rating: A Category: Reproductive / Hormonal
Buserelin is a synthetic GnRH agonist nonapeptide analog (MW ~1299.5 g/mol) with a D-Ser(tBu) substitution at position 6 and an NHEt modification at position 10. It is approved in the European Union, Canada, Australia, and other countries for the treatment of advanced prostate cancer, endometriosis,...
Key claims: Effective androgen deprivation in prostate cancer; Treats endometriosis-associated pain.
PNC-27 — Animal/Preclinical Only
Evidence Rating: D Category: Cancer Research
PNC-27 is a chimeric peptide (~3,000 g/mol) composed of a p53 protein binding domain fused to a cell-penetrating/membrane-lytic domain. It is designed to selectively bind HDM-2 (human homolog of MDM-2) expressed on the surface of cancer cells, creating membrane pores that trigger necrosis specifical...
Key claims: Selectively kills cancer cells; Effective across multiple cancer types in vitro.
Related Research News
Leuprolide Acetate's Key Role in Reproductive Disorders
Leuprolide acetate acts as a synthetic GnRH agonist to treat various reproductive system issues, including prostate cancer and central precocious puberty. It suppresses gonadotropin secretion, reducing testosterone to levels seen after orchiectomy, which helps manage prostate cancer effectively. Research also shows potential benefits in conditions like endometriosis, breast cancer, and even spinal cord recovery.
Triptorelin: Synthetic GnRH Agonist for Hormone Research
Triptorelin serves as a synthetic gonadotropin-releasing hormone agonist that regulates hormone levels for research into conditions like prostate cancer and endometriosis. It initially stimulates then desensitizes the pituitary gland, reducing LH, FSH, testosterone, and estrogen. Studies highlight its role in managing precocious puberty, breast cancer, and women's health issues, with a specific structure and proven efficacy in clinical trials.